Clinical Performance of Two Automated Immunoassays, EliA CTD Screen and QUANTA Flash CTD Screen Plus, for Antinuclear Antibody Screening
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: Recently, two fully automated immunoassays for antinuclear antibody (ANA) screening were introduced: EliA CTD Screen (Thermo Fisher Scientific, Freiburg, Germany) and QUANTA Flash CTD Screen Plus (Inova Diagnostics, San Diego, USA). We evaluated their clinical performance in comparison with the indirect immunofluorescence assay (IIFA) and analyzed samples with discrepant results. Methods: In total, 406 serum samples (206 from patients undergoing routine checkups and 200 from rheumatology clinic patients) were assayed using EliA, QUANTA Flash, and IIFA. We evaluated assay concordance and agreement and confirmed the presence of anti-extractable nuclear antigen (ENA) antibodies in samples with discrepant automated immunoassay and IIFA results. Additionally, we compared the clinical performance of each assay in diagnosing ANA-associated rheumatic disease (AARD) and adjusted the cut-off values. Results: In rheumatology clinic samples, the concordance and agreement were 91.5% and strong between EliA and QUANTA Flash, 79.0% and weak between EliA and IIFA, and 80.5% and moderate between QUANTA Flash and IIFA, respectively. In automated immunoassay-positive, IIFA-negative samples (N=15), all anti-ENA antibodies detected (6/15) were anti-Sjögren’s syndrome antigen A/Ro (Ro60) antibodies. The automated immunoassays and IIFA showed high accuracy for diagnosing AARD, and adjusted cut-off values improved their sensitivities (EliA with 0.56 ratio, 82.9% sensitivity; QUANTA Flash with 9.7 chemiluminescent units, 87.8% sensitivity). Conclusions: The two automated immunoassays showed reliable performance compared with IIFA and can be efficiently used with the IIFA in clinical immunology laboratories. Clinical cut-off values can be adjusted according to the workflow in each laboratory.
Abstract
Background: Recently, two fully automated immunoassays for antinuclear antibody (ANA) screening were introduced: EliA CTD Screen (Thermo Fisher Scientific, Freiburg, Germany) and QUANTA Flash CTD Screen Plus (Inova Diagnostics, San Diego, USA). We evaluated their clinical performance in comparison with the indirect immunofluorescence assay (IIFA) and analyzed samples with discrepant results. Methods: In total, 406 serum samples (206 from patients undergoing routine checkups and 200 from rheumatology clinic patients) were assayed using EliA, QUANTA Flash, and IIFA. We evaluated assay concordance and agreement and confirmed the presence of anti-extractable nuclear antigen (ENA) antibodies in samples with discrepant automated immunoassay and IIFA results. Additionally, we compared the clinical performance of each assay in diagnosing ANA-associated rheumatic disease (AARD) and adjusted the cut-off values. Results: In rheumatology clinic samples, the concordance and agreement were 91.5% and strong between EliA and QUANTA Flash, 79.0% and weak between EliA and IIFA, and 80.5% and moderate between QUANTA Flash and IIFA, respectively. In automated immunoassay-positive, IIFA-negative samples (N=15), all anti-ENA antibodies detected (6/15) were anti-Sjögren’s syndrome antigen A/Ro (Ro60) antibodies. The automated immunoassays and IIFA showed high accuracy for diagnosing AARD, and adjusted cut-off values improved their sensitivities (EliA with 0.56 ratio, 82.9% sensitivity; QUANTA Flash with 9.7 chemiluminescent units, 87.8% sensitivity). Conclusions: The two automated immunoassays showed reliable performance compared with IIFA and can be efficiently used with the IIFA in clinical immunology laboratories. Clinical cut-off values can be adjusted according to the workflow in each laboratory.
참고문헌 (28)
- Solomon DH, "Evidence-based guidelines for the use of immunologic tests : antinuclear antibody testing", Arthritis Rheum, 47, pp.434~444 (2002)
- Mahler M, "Current concepts and future directions for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies", J Immunol Res, 2014, pp.315179~ (2014)
- van der Pol P, "Analytical and clinical comparison of two fully automated immunoassay systems for the detection of autoantibodies to extractable nuclear antigens", Clin Chim Acta, 476, pp.154~159 (2018)
- Claessens J, "Solid phase assays versus automated indirect immunofluorescence for detection of antinuclear antibodies", Autoimmun Rev, 17, pp.533~540 (2018)
- Aringer M, "2019 European League Against Rheumatism", American College of Rheumatology classification criteria for systemic lupus erythematosus, 2019, pp.71, 1400~1412
- Alicja Bauer, "Detection of Autoantibodies Against Nucleoporin p62 in Sera of Patients With Primary Biliary Cholangitis", Annals of Laboratory Medicine, 39(3), pp.291~298 (2019), 대한진단검사의학회[DOI]
- Agmon-Levin N, "International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies", Ann Rheum Dis, 73, pp.17~23 (2014)
- Peterson LK, "Assessment of antinuclear antibodies by indirect immunofluorescence assay : report from a survey by the American Association of Medical Laboratory Immunologists", Clin Chem Lab Med, 58, pp.1489~1497 (2020)
- 유인영, "Performance of an Automated Fluorescence Antinuclear Antibody Image Analyzer", Annals of Laboratory Medicine, 37(3), pp.240~247 (2017), 대한진단검사의학회
- Shovman O, "Evaluation of the BioPlex 2200 ANA screen : analysis of 510 healthy subjects : incidence of natural", predictive autoantibodies, 2005, pp.1050, 380~388
- Shovman O, "Multiplexed AtheNA multi-lyte immunoassay for ANA screening in autoimmune diseases", Autoimmunity, 38, pp.105~109 (2005)
- Bentow C, "Clinical performance evaluation of a novel, automated chemiluminescent immunoassay, QUANTA Flash CTD Screen Plus", Immunol Res, 61, pp.110~116 (2015)
- Jeong S, "Evaluation of an automated connective tissue disease screening assay in Korean patients with systemic rheumatic diseases", PLoS One, 12, pp.e0173597~ (2017)
- Jeong S, "Evaluation of an automated screening assay, compared to indirect immunofluorescence, an extractable nuclear antigen assay, and a line immunoassay in a large cohort of Asian patients with antinuclear antibody-associated rheumatoid diseases: a multicenter retrospective study", J Immunol Res, 2018, pp.9094217~ (2018)
- Parker JC, "Sensitivity of the Phadia EliA connective tissue disease screen for less common disease-specific autoantibodies", J Clin Pathol, 64, pp.631~633 (2011)
- Aksu G, "Determination of cut-offtiters and agreement between immunofluorescence and immunoblotting methods for detecting antinuclear antibodies in children", J Clin Lab Anal, 24, pp.230~236 (2010)
- Garbati M, "Diagnosis of pulmonary tuberculosis : utility of serology and Mantoux reaction in a resource-limited setting", Internet J Infect Dis, 8 (2009)
- McHugh ML, "Interrater reliability : the kappa statistic", Biochem Med, 22, pp.276~282 (2012)
- Greiner M, "Principles and practical application of the receiver-operating characteristic analysis for diagnostic tests", Prev Vet Med, 45, pp.23~41 (2000)
- Op De Beeck K, "Detection of antinuclear antibodies by indirect immunofluorescence and by solid phase assay", Autoimmun Rev, 10, pp.801~808 (2011)
- Hoffman IE, "Detection of specific antinuclear reactivities in patients with negative anti-nuclear antibody immunofluorescence screening tests", Clin Chem, 48, pp.2171~2176 (2002)
- Bossuyt X, "Antibodies to extractable nuclear antigens in antinuclear antibody-negative samples", Clin Chem, 51, pp.2426~2427 (2005)
- Egner W, "The use of laboratory tests in the diagnosis of SLE", J Clin Pathol, 53, pp.424~432 (2000)
- Gussin HA, "Anti-topoisomerase I(anti-Scl-70)antibodies in patients with systemic lupus erythematosus", Arthritis Rheum, 44, pp.376~383 (2001)
- González C, "Anti-nucleosome, anti-chromatin, anti-dsDNA and anti-histone antibody reactivity in systemic lupus erythematosus", Clin Chem Lab Med, 42, pp.266~272 (2004)
- Satoh M, "Clinical interpretation of antinuclear antibody tests in systemic rheumatic diseases", Mod Rheumatol, 19, pp.219~228 (2009)
- Kern P, "Measurement of antinuclear antibodies : assessment of different test systems", Clin Diagn Lab Immunol, 7, pp.72~78 (2000)
- O’Sullivan M, "Antinuclear antibody test", Aust Fam Physician, 42, pp.718~721 (2013)